Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

• Main Authors: R. Caporali (Author), M. Filippini (Author), R. Gorla (Author), E.G. Favalli (Author), A. Marchesoni (Author), M. Antivalle (Author), P. Sarzi- Puttini (Author), F. Bobbio-Pallavicini (Author), C. Montecucco (Author), F. Atzeni (Author)
• Format: Book
• Published: PAGEPress Publications, 2011-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treati...